Compare TVRD & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TVRD | XLO |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 39.4M |
| IPO Year | N/A | 2021 |
| Metric | TVRD | XLO |
|---|---|---|
| Price | $3.68 | $7.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $51.67 | $28.00 |
| AVG Volume (30 Days) | 37.3K | ★ 329.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $0.46 |
| 52 Week High | $43.65 | $8.09 |
| Indicator | TVRD | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 92.97 |
| Support Level | N/A | $0.63 |
| Resistance Level | $4.39 | N/A |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | -0.02 | 0.85 |
| Stochastic Oscillator | 32.15 | 91.38 |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.